Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Rubina Ghani

Rubina Ghani

Jinnah Medical and Dental College, Pakistan

Title: Platelet rich plasma use in the treatment of eczema (atopic dermatitis): A case report

Biography

Biography: Rubina Ghani

Abstract

Background: In the last few decades, thousands of patients have benefited from platelet-rich plasma (PRP) therapies, emerging as a safe alternative in many different medical fields. The use of Platelet-Rich Plasma (PRP) in medicine has become increasingly more widespread during the last decade. Eczema (atopic dermatitis) is a complex disorder caused by the interplay between multiple genetic and environmental factors. Particularly in patients with severe disease, the effect is not just an itchy rash but also the secondary effects on the psychological well-being of the patient and their carers, particularly disturbed sleep. The aim of the study was to treat the patient by using the platelet-rich plasma.

Materials and Methods: 15cc blood sample was collected from the patient. The baseline parameters included complete blood count (CBC), erythrocyte sedimentation rate(ESR), fasting blood sugar/ransom blood sugar(FBS/RBS), urea, creatinine and uric acid, We also checked for the inflammation by performing C-Reactive Protein(CRP) and immunoglobulin IgE for the allergy. The rest of the blood sample was used for the PRP.The platelet-rich plasma (PRP) was collected with the help of spiral needle in sterilized falcon tube which was then place in Adilight 2 for the activation of PRP for 15minutes.

Result: In baseline reports, it was noted that eosinophil was elevated, with ESR. The sugar level, urea, creatinine and Uric acid were at the normal range. The CRP was high and igE was abnormal. She underwent three consecutive platelet-rich plasma therapy with a gap of 15 days in between. We assessed the patients by taking the photograph and repeating the parameters which were elevated before the second and third treatment. After the first therapy, the images showed improvement. However, after the second therapy, the patient reported marked control on the itchy and disappearance of rash. She was quite satisfied with the treatment because of the treatment she was taking increasing the rashes.

Conclusion: This study suggests the use of platelet-rich plasma has a beneficial effect on skin diseases and can thus be attributed to various platelet-derived growth factors causing improvement in the function on skin and promotion to decrease the rashes and itching. It is safe, cheap and non-allergic and it appears to be a useful adjuvant in the management of eczema.